Methods for in vitro evolution of constructs derived from viruses

Patent metadata

Field	Value
Publication number	US-12286646-B2
Application number	US-202016739182-A
Country	US
Kind code	B2
Filing date	Jan 10, 2020
Priority date	Jan 10, 2019
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

The disclosure provides methods for an in vitro evolution technique to identify and characterize mutations in the non-structural genes of an alphavirus replicon that increase the strength and persistence of expression of the replicon genome. Also provided herein are in vivo methods for administering to an animal model a mutated alphavirus replicon that codes for a gene of experimental or therapeutic interest in the subgenome of the alphavirus replicon. The mutations identified herein improve the therapeutic potential of self-replicating RNA, which may have implications for cancer immunotherapy and beyond, e.g., for vaccination or gene therapy.

First claim

What is claimed is:

1. A nucleic acid molecule comprising a nucleotide sequence as shown in any one of SEQ ID NOs: 1-18, or any combination of two or more of SEQ ID NOs: 1-18.

2. A nucleic acid molecule comprising a portion of a nucleotide sequence as shown in any one of SEQ ID NOs: 1-18, or any combination of two or more portions of SEQ ID NOs: 1-18, wherein the portion of the nucleotide sequence comprises a combination of two or more mutations relative to the corresponding wild-type Venezuelan equine encephalitis (VEE) virus ribonucleic acid (RNA) selected from the group consisting of A1979G, G3936C, A4311G, A4758G, G4796T, and G4944A, wherein the position of the mutation(s) is relative to SEQ ID NO: 1.

3. An alphavirus replicon comprising the nucleic acid molecule of claim 2 .

4. The replicon of claim 3 , wherein the replicon encodes non-structural proteins for replication, but does not encode structural proteins for viral formation.

5. The replicon of claim 3 , wherein the replicon comprises the untranslated regions, non-structural proteins, and subgenomic promoter of the alphavirus.

6. The replicon of claim 3 , wherein the structural proteins of the replicon are replaced by one or more gene(s) of experimental or therapeutic interest.

7. The replicon of claim 6 , wherein the one or more gene(s) of experimental or therapeutic interest encodes Interleukin-2 (IL-2) or luciferase.

8. The replicon of claim 3 , wherein the replicon is engineered to express a detectable molecule in the subgenomic region of the replicon.

9. The replicon of claim 8 , wherein the detectable molecule is a fluorescent protein.

10. The nucleic acid molecule of claim 2 , wherein the portion of the nucleotide sequence is at least 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides in length.

11. The replicon of claim 6 , wherein the one or more gene(s) encode cytokines, chemokines, or growth factors.

12. The replicon of claim 8 , wherein the detectable molecule is a nucleic acid or polypeptide.

13. The replicon of claim 9 , wherein the fluorescent protein is mCherry, mKate, blue fluorescent protein, yellow fluorescent protein, red fluorescent protein, mVenus, green fluorescent protein, mRaspberry, or mStrawberry.

14. An alphavirus replicon comprising the nucleic acid molecule of claim 1 .

15. The replicon of claim 14 , wherein the replicon encodes non-structural proteins for replication, but does not encode structural proteins for viral formation.

16. The replicon of claim 15 , wherein the structural proteins of the alphavirus replicon are replaced by one or more gene(s) of experimental or therapeutic interest.

17. The replicon of claim 16 , wherein the one or more gene(s) of experimental or therapeutic interest encodes Interleukin-2 (IL-2) or luciferase.

18. The replicon of claim 15 , wherein the alphavirus replicon is engineered to express a detectable molecule in the subgenomic region of the replicon.

19. The replicon of claim 18 , wherein the detectable molecule is a nucleic acid or polypeptide.

20. The replicon of claim 18 , wherein the detectable molecule is a fluorescent protein.

Assignees

• Massachusetts Inst Technology

Inventors

• Irvine Darrell J
• Weiss Ron
• Li Yingzhong

Classifications

• C12N2770/36171

  Demonstrated in vivo effect · CPC title

• C12N2770/36143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2770/36121

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title

• C12N15/1096

  cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR · CPC title